Barclays
QNRX

Barclays’s Quoin Pharmaceuticals QNRX Stock Holding History

Barclays’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
21,469
+20,169
+1,551% +$109K ﹤0.01% 4026
2026
Q1 		$8.58K Buy
+1,300
New +$11.8K ﹤0.01% 4720

Other funds holding QNRX

DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Barclays's QNRX Position: Q2 2026 in Review

Barclays increased its Quoin Pharmaceuticals (QNRX) stake by 1,551% in Q2 2026, buying an estimated $109K and bringing the position to 21,469 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4026.

Barclays first reported a position in QNRX in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold QNRX as of Q2 2026.

  • Barclays held 21,469 shares of Quoin Pharmaceuticals worth $104K as of Q2 2026.
  • Barclays bought 20,169 Quoin Pharmaceuticals shares in Q2 2026, an estimated $109K.
  • Quoin Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4026 holding.
  • Barclays first reported a position in Quoin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.